Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Fresenius Health Partners, InterWell Health, and Cricket Health have merged to form InterWell Health. We are setting the new standard in value-based kidney care in the U.S., driving innovation and transformation in the industry. Visit TransformingKidneyCare.com for more information.
Success! The link has been copied to your clipboard.
WALTHAM, MASS. – Sept. 10, 2019 – Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, announces record growth in home dialysis in the six months since its merger with NxStage Medical Inc. The growth rate for home dialysis is now eight times the rate of in-center dialysis*, and the company has surpassed 25,000 patients currently receiving treatment at home.
“As the industry leader in dialysis products and services, we are committed to actively shaping the future of patient care to provide the best quality of life for people living with kidney failure,” said Bill Valle, Chief Executive Officer of Fresenius Medical Care North America. “We want to ensure home dialysis is offered as the best option if transplant is not feasible, and are focused on giving life back to this patient population.”
A recent presidential executive order highlighted the benefits of home dialysis, with the Centers for Medicare and Medicaid Services (CMS) encouraging the shift to home therapies through new policy development. In 2019 alone, Fresenius Medical Care North America has achieved these additional home dialysis initiatives and milestones:
Many experts agree that home dialysis — either peritoneal or hemodialysis — is the best option aside from transplant for treating kidney failure. Choosing home dialysis can mean fewer food restrictions, greater scheduling flexibility, less frequent transportation challenges, and better outcomes.
“Research shows that home dialysis often leads to better outcomes for patients,” said Dr. Robert Kossmann, Chief Medical Officer for FMCNA. “We are driven to make the choice of home therapies even easier through innovation, research, technology, investment, and personalized patient care. It’s incredibly exciting to see the increasing support for home therapy among nephrologists and the government.”
The company continues to offer meaningful, educational information to the public through its Fresenius Kidney Care patient-facing website and its Fresenius Medical Care North America website and newsroom.
*Based on growth rates for the six month period from March 2019 through August 2019.
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.